C.Q. Pharmaceutical Holding Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Chongqing Pharmaceutical Holdings Co., Ltd. is a large state-owned modern pharmaceutical circulation enterprise that serves the entire pharmaceutical industry chain, while also engaged in pharmaceutical research and development, medical device production, and investing in the pharmaceutical industry. The company is listed on the Shenzhen Stock Exchange with stock code 000950. The operating entity of the listed company, Chongqing Pharmaceutical (Group) Co., Ltd., formerly known as the Southwest Branch of China Pharmaceutical Company established in 1950, is a designated reserve unit for drugs and medical devices at the central and local levels. It is also one of the only three national wholesale enterprises operating anesthetic drugs and first class psychotropic drugs in China, with a leading enterprise scale and market coverage in the western region. In 2021, the company's operating revenue was 62.521 billion yuan, with a total profit of 1.58 billion yuan, an increase of 38.26% and 14.97% respectively compared to the previous year. The company paid 1.38 billion yuan in taxes, ranking among the top five pharmaceutical commercial enterprises in China. It has over 200 subsidiaries and branches at all levels, with over 14000 employees, and is located in 27 provinces, cities, and autonomous regions across the country. The main business of the pharmaceutical commercial sector includes hospital pure sales, commercial wholesale, retail chain, terminal distribution, warehousing logistics, and supply chain value-added services for drugs, medical devices, traditional Chinese medicine decoction pieces, and health products. The marketing network covers 31 provinces (cities, autonomous regions) nationwide, and was the first in the 2019 new round of medical reform "4+7" volume procurement work, laying a solid foundation for the expansion of volume procurement work in 2020. The company has built a leading "medicine+internet" platform for Chinese pharmaceutical commerce, carrying out B2B, B2C, O2O and other pharmaceutical e-commerce businesses. Through information technology support such as the internet, the Internet of Things, artificial intelligence, big data applications, and mobile terminals, the company provides auxiliary medical services such as chronic disease management, electronic prescription circulation, out of hospital pharmaceutical management, and remote diagnosis and treatment. The company's nationally renowned brands "Peace Pharmacy" and "New Health Pharmacy" have over 800 stores distributed in 16 provinces, cities, autonomous regions, including Sichuan, Chongqing, and Guizhou. We have an online shopping mall at Heping Pharmacy, as well as businesses such as in-house self funded pharmacies, DTP specialty drug delivery, and hospital infusion centers. The company has a leading modern pharmaceutical logistics distribution center in China, with multiple distribution centers set up in the country, with a storage area of over 492000 square meters. It also utilizes intelligent logistics technology in the hospital to cooperate with large comprehensive hospitals, achieve warehouse forward movement, complement the advantages of small and medium-sized hospitals and regional medical centers, and build a central warehouse to achieve centralized distribution. In terms of pharmaceutical research and development, we adhere to the development concept of innovation and establish a comprehensive new drug research and development system that conforms to the company's strategic planning. Adopting international standards, invest, screen, cultivate, and apply for a batch of high value-added chemical drugs, traditional Chinese medicine, biological products, and medical device products that meet the company's development field. At the same time, fully utilize the company's existing pharmaceutical commercial circulation channels, retail networks, and medical institutions to drive the marketing and promotion of new products, and achieve industrial coordinated development. At present, the company is upgrading and transforming from a traditional distribution business enterprise to a "Internet plus medicine" integrated modern medicine business, cultivating a strong sustainable competitiveness. The company adheres to the corporate spirit of "dedicating oneself to medicine and pursuing excellence", adheres to the core values of "responsibility, people-oriented, harmonious, and grateful", and based on the significant opportunities for the development of the pharmaceutical and health industry, adheres to innovative development, and is committed to building a first-class and internationally renowned pharmaceutical and health industry group in China. |
| Headquarter | Chongqing |
| Establish Date | 5/28/1999 |
| Listed Code | 000950.SZ |
| Listed Date | 9/16/1999 |
| Chairman | Yuan Quan. |
| CEO | Liu Wei. |
| Website | www.cqphar.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
